Kevin Caldwell, Ossium Health CEO, on Cell Therapy, Vertical Integration & Immune Healthspan

Synopsis: From stargazing in rural Tennessee to reimagining the future of immune health, Kevin Caldwell’s journey is anything but conventional. In this episode of Biotech2050, Rahul Chaturvedi speaks with the CEO, Co-Founder & President of Ossium Health about how personal experiences with a reactive healthcare system—and a deep curiosity about the universe—sparked a mission to extend human healthspan through regenerative medicine. Kevin shares how Ossium built the first scalable bone marrow bank sourced from deceased organ donors—unlocking a powerful, overlooked source for life-saving cell therapies. He discusses Ossium’s fully integrated model, commercialization strategy, and why rigorous company-building must go hand-in-hand with scientific ambition. The conversation unpacks hard-won lessons from raising $130M+, navigating regulatory pathways, and leading with long-term conviction. A bold vision for transforming cell therapy—and a candid look at the mindset needed to build for impact. Biography: As CEO, Co-Founder & President of Ossium Health, Kevin Caldwell has built Ossium from a small startup into a clinical stage bioengineering company. Mr. Caldwell set the company’s mission to improve human health through bioengineering and designed its platform-based model for cellular therapeutics development. Mr. Caldwell has led the company’s successful pursuit, negotiation, and execution of more than 50 business relationships, including 5 successful fundraisings and dozens of supply partnerships, clinical partnerships, and commercial contracts with biopharmaceutical companies. After seven years of strategic engagement and networking, Mr. Caldwell drove the team to successfully secure a transformative federal contract with BARDA (Biomedical Advanced Research and Development Authority) that validates Ossium’s innovative approach. This milestone represents the culmination of persistent relationship-building, targeted proposals, and our unwavering commitment to addressing national biomedical challenges through cutting-edge technology and collaborative partnerships. Prior to founding Ossium, Mr. Caldwell served as an Engagement Manager at McKinsey’s San Francisco office where he advised clients in the biotechnology and healthcare sectors. His projects ranged from due diligence of acquisition targets in the biotech startup ecosystem to restructuring distressed biopharma companies. Mr. Caldwell led more than 20 engagements with more than a dozen clients, leading teams that advised clients on revenue growth, go to market strategy, and organizational restructuring. Before McKinsey, Mr. Caldwell served as a Senior Investment Associate at Bridgewater Associates where he did quantitative research for the firm’s global macro investments. Mr. Caldwell studied Physics and Economics at MIT before receiving his JD from Harvard Law School. In addition, he is a member of the Young Presidents Organization (YPO), and a Fellow of the Leaders in Tech Program.